ClinicalTrials.gg
CompletedNCT00654628BRAVOUpdated May 22, 2024Results posted

Begin With The Right Patients With Dual-Inhibition Action Therapy Through Vytorin for Newly Diagnosed Dyslipidemia Patients (0653A-172)(COMPLETED)

A Phase 4 interventional study of ezetimibe (+) simvastatin in Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 20 Years to 79 Years. Per ClinicalTrials.gov, last updated 2024-05-22.

Sponsored by Organon and Co · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Aug 2007, registered Apr 2008).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
173
Allocation
Non-randomized
Ages
20 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.

Enrollment
41st of 97
173 · median 148
Started
2007
with 15 others
Phase 4
31 of 98
1 open now
Registered
50th of 98
by date
Lead sponsor
55 of 98
Organon and Co

Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 41st largest by enrollment of the 97 interventional ones that give a count, is one of 16 that started in 2007, is one of 31 in phase 4, and was the 50th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ezetimibe

Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 20 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing ezetimibe in Hypercholesterolemia, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety and tolerability of ezetimibe/simvastatin in patients newly diagnosed with dyslipidemia.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
20 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male Or Female Patient, 20 Through 79 Years Of Age
  • Newly Diagnosed Dyslipidemia Patients Including: 1) Intermediate Risk (>2 Risk Factors) With Total Cholesterol level above 200 mg/dL Or Low Density Lipoprotein-C (LDL-C) level> 130 mg/dLwho failed a 3-Month diet control period, or 2) High Risk Patients with history of Coronary artery disease Or diabetes and having a total Cholesterol> 200 mg/dL Or LDL-C level> 130 mg/dL
  • Willing To Follow An National Cholesterol Education Program (NCEP) Therapeutic Lifestyle Changes (TLC) Or Similar Cholesterol-Lowering Diet For The Duration Of The Study
  • Female Patients Receiving Hormone Therapy (Including Hormone Replacement Therapy, And Estrogen Antagonist/Agonist, Or Oral ) If Maintained On A Stable Dose And Regimen For At Least 8 Weeks Prior To Visit 1 And If Willing To Continue The Same Regimen Throughout The Study

Exclusion criteria

Exclusion Criteria:

  • Women Who Are Pregnant Or Lactating
  • Has A History Of Cancer Within The Past 5 Years (Except For Dermatological Basal Cell Or Squamous Cell Carcinoma)
  • Patients Hypersensitive To Simvastatin Or Ezetimibe
  • Any Condition Or Situation Which, In The Opinion Of The Investigator, Might Pose A Risk To The Patient Or Confound The Results Of The Study
  • History Of Mental Instability, Drug/Alcohol Abuse Within The Past 5 Years, Or Major Psychiatric Illness Not Adequately Controlled By Pharmacotherapy
  • Nephritic Syndrome Or Other Renal Disease Resulting In Impaired Renal Function, Defined As Serum Creatinine ≧ 1.5 Mg/Dl
  • (ALT), And Aspartate Aminotransferase (AST) above 1.5 X (Uln) Or With Active Liver Disease
  • Congestive Heart Failure ( (NYHA) III Or IV), Uncontrolled Cardiac Arrythmias, Uncontrolled Hypertension (Systolic Blood Pressure (SBP) >160 mm Hg Or Diastolic Blood Pressure (DBP) >100 mm Hg), Unstable Angina Pectoris Or Severe Peripheral Artery Disease, Or Experienced Myocardial Infarction, Coronary Artery Bypass Surgery, Angioplasty Within 3 Months
  • Unstable Diabetes Mellitus Patient ( (HbA1c) > 8.5%) Or Newly Diagnosed (Within 3 Months) Or A Change In Anti-Diabetic Pharmacotherapy Within 3 Months Of Screening
  • Secondary Dyslipidemia (E.G., Hypothyroidism)
  • Disorders Of The Hematologic, Digestive, Or Central Nervous Systems Including Cerebrovascular Disease And Degenerative Disease That Would Limit Study Evaluation Or Participation
  • History Of Active Or Chronic Hepatobiliary Disease Or Cholelithiasis But Have Not Undergone Cholecystectomy
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
173 participants (actual)

Study arms

  • Experimental
    1

    Patients with intermediate or high risk dyslipidemia will be enrolled to receive treatment with Vytorin 10/20 (ezetimibe 10 mg /simvastatin20 mg) tablet once daily consecutively for 6 weeks

    Drug: ezetimibe (+) simvastatin

Interventions

  • Drugezetimibe (+) simvastatin

    Drug pages: Ezetimibe · Simvastatin

    Vytorin 10/20 (ezetimibe 10 mg /simvastatin20 mg) tablet once daily consecutively for 6 weeks.

    Also known as: Vytorin®, MK653A

06

What researchers measure

Primary outcomes

  1. The Percentage of Participants Achieving Low Density Lipoprotein-C (LDL-C) Treatment Goal After 6-week Treatment.

    Goal attainment percentage of LDL-C after 6-week treatment. LDL-C goal attainment was based on National Cholesterol Education program (NCEP) Adult Treatment Panel (ATP) III guidelines (2004). Newly Diagnosed Dyslipidemia Patients Including: 1)Intermediate Risk (\>2 Risk Factors) with Total Cholesterol above 200 mg/dL or Low Density Lipoprotein C (LDL-C) level \>130 who failed a 3-month diet control period, or 2) high risk patients with a history of coronary artery disease or diabetes having a total cholesterol \>200 mg/dl or LDL-C level \>130 mg/dl.

    Time frame: Baseline and week 6

  2. The Percentage of Participants Achieving Low Density Lipoprotein-C (LDL-C) Treatment Goal After 12-week Treatment.

    Goal attainment percentage of LDL-C after 12-week treatment. LDL-C goal attainment was based on National Cholesterol Education program (NCEP) Adult Treatment Panel (ATP) III guidelines (2004). Newly Diagnosed Dyslipidemia Patients Including: 1)Intermediate Risk (\>2 Risk Factors) with Total Cholesterol above 200 mg/dL or Low Density Lipoprotein C (LDL-C) level \>130 who failed a 3-month diet control period, or 2) high risk patients with a history of coronary artery disease or diabetes having a total cholesterol \>200 mg/dl or LDL-C level \>130 mg/dl.

    Time frame: Baseline and week 12

Secondary outcomes

  1. Mean Percent Change From Baseline of Low Density Lipoprotein-Cholesterol (LDL-C) at Week 6

    Time frame: Baseline and week 6

  2. Mean Percent Change From Baseline of Total-Cholesterol (TC) at Week 6

    Time frame: Baseline and week 6

  3. Mean Percent Change From Baseline of High Density Lipoprotein-C (HDL-C) at Week 6

    Time frame: Baseline and week 6

  4. Mean Percent Change of Triglycerides From Baseline at Week 6

    Time frame: Baseline and week 6

  5. Mean Percent Change From Baseline of Low Density Lipoprotein-Cholesterol (LDL-C) at Week 12

    Time frame: Baseline and week 12

  6. Mean Percent Change From Baseline of Total-Cholesterol (TC) at Week 12

    Time frame: Baseline and week 12

  7. Mean Percent Change From Baseline of High Density Lipoprotein-C (HDL-C) at Week 12

    Time frame: Baseline and week 12

  8. Mean Percent Change of Triglycerides From Baseline at Week 12

    Time frame: Baseline and week 12

Other outcomes

  1. Mean Change From Baseline of Low Density Lipoprotein-Cholesterol (LDL-C) at Week 6

    Time frame: Baseline and week 6

  2. Mean Change From Baseline of Low Density Lipoprotein-Cholesterol (LDL-C) at Week 12

    Time frame: Baseline and week 12

07

Results

Posted Aug 26, 2010

Participant flow

Patients were recruited between August 2007 and July 2009. In one site, 60 patients among the total 152 study population entered into the 6-week extension period after completing the base period for longer follow-up as per IRB requirement in that site.

6-week Active Treatment Period
Participant flow — 6-week Active Treatment Period
MilestoneEzetimibe/Simvastatin 10/20 mg
Started173
Completed152
Not completed21
Withdrew: Adverse event9
Withdrew: Lost to follow-up10
Withdrew: Transferred to branch hospital1
Withdrew: Out of window period1
6 -Week Extension Period (Single Site)
Participant flow — 6 -Week Extension Period (Single Site)
MilestoneEzetimibe/Simvastatin 10/20 mg
Started60
Completed55
Not completed5
Withdrew: Adverse event4
Withdrew: Lost to follow-up1

Outcome measures

PrimaryThe Percentage of Participants Achieving Low Density Lipoprotein-C (LDL-C) Treatment Goal After 6-week Treatment.

Goal attainment percentage of LDL-C after 6-week treatment. LDL-C goal attainment was based on National Cholesterol Education program (NCEP) Adult Treatment Panel (ATP) III guidelines (2004). Newly Diagnosed Dyslipidemia Patients Including: 1)Intermediate Risk (\>2 Risk Factors) with Total Cholesterol above 200 mg/dL or Low Density Lipoprotein C (LDL-C) level \>130 who failed a 3-month diet control period, or 2) high risk patients with a history of coronary artery disease or diabetes having a total cholesterol \>200 mg/dl or LDL-C level \>130 mg/dl.

Time frame:
Baseline and week 6
Reported as:
Number · Percentage of participants
The Percentage of Participants Achieving Low Density Lipoprotein-C (LDL-C) Treatment Goal After 6-week Treatment.
Percentage of participantsEzetimibe/Simvastatin 10/20 mg
The Percentage of Participants Achieving Low Density Lipoprotein-C (LDL-C) Treatment Goal After 6-week Treatment.90.4
PrimaryThe Percentage of Participants Achieving Low Density Lipoprotein-C (LDL-C) Treatment Goal After 12-week Treatment.

Goal attainment percentage of LDL-C after 12-week treatment. LDL-C goal attainment was based on National Cholesterol Education program (NCEP) Adult Treatment Panel (ATP) III guidelines (2004). Newly Diagnosed Dyslipidemia Patients Including: 1)Intermediate Risk (\>2 Risk Factors) with Total Cholesterol above 200 mg/dL or Low Density Lipoprotein C (LDL-C) level \>130 who failed a 3-month diet control period, or 2) high risk patients with a history of coronary artery disease or diabetes having a total cholesterol \>200 mg/dl or LDL-C level \>130 mg/dl.

Time frame:
Baseline and week 12
Reported as:
Number · Percentage of participants
The Percentage of Participants Achieving Low Density Lipoprotein-C (LDL-C) Treatment Goal After 12-week Treatment.
Percentage of participantsEzetimibe/Simvastatin 10/20 mg
The Percentage of Participants Achieving Low Density Lipoprotein-C (LDL-C) Treatment Goal After 12-week Treatment.87.8
SecondaryMean Percent Change From Baseline of Low Density Lipoprotein-Cholesterol (LDL-C) at Week 6
Time frame:
Baseline and week 6
Reported as:
Mean · Percent Change
Mean Percent Change From Baseline of Low Density Lipoprotein-Cholesterol (LDL-C) at Week 6
Percent ChangeEzetimibe/Simvastatin 10/20 mg
Mean Percent Change From Baseline of Low Density Lipoprotein-Cholesterol (LDL-C) at Week 6-51.4 ± 15.6
SecondaryMean Percent Change From Baseline of Total-Cholesterol (TC) at Week 6
Time frame:
Baseline and week 6
Reported as:
Mean · Percent Change
Mean Percent Change From Baseline of Total-Cholesterol (TC) at Week 6
Percent ChangeEzetimibe/Simvastatin 10/20 mg
Mean Percent Change From Baseline of Total-Cholesterol (TC) at Week 6-38.1 ± 11.3
SecondaryMean Percent Change From Baseline of High Density Lipoprotein-C (HDL-C) at Week 6
Time frame:
Baseline and week 6
Reported as:
Mean · Percent Change
Mean Percent Change From Baseline of High Density Lipoprotein-C (HDL-C) at Week 6
Percent ChangeEzetimibe/Simvastatin 10/20 mg
Mean Percent Change From Baseline of High Density Lipoprotein-C (HDL-C) at Week 64.5 ± 15.8
SecondaryMean Percent Change of Triglycerides From Baseline at Week 6
Time frame:
Baseline and week 6
Reported as:
Median · Percent Change
Mean Percent Change of Triglycerides From Baseline at Week 6
Percent ChangeEzetimibe/Simvastatin 10/20 mg
Mean Percent Change of Triglycerides From Baseline at Week 6-22.2 (-43.6 to 0)
Other pre-specifiedMean Change From Baseline of Low Density Lipoprotein-Cholesterol (LDL-C) at Week 6
Time frame:
Baseline and week 6
Reported as:
Mean · mg/dL
Mean Change From Baseline of Low Density Lipoprotein-Cholesterol (LDL-C) at Week 6
mg/dLEzetimibe/Simvastatin 10/20 mg
Mean Change From Baseline of Low Density Lipoprotein-Cholesterol (LDL-C) at Week 6-82.0 ± 30.8
SecondaryMean Percent Change From Baseline of Low Density Lipoprotein-Cholesterol (LDL-C) at Week 12
Time frame:
Baseline and week 12
Reported as:
Mean · Percent Change
Mean Percent Change From Baseline of Low Density Lipoprotein-Cholesterol (LDL-C) at Week 12
Percent ChangeEzetimibe/Simvastatin 10/20 mg
Mean Percent Change From Baseline of Low Density Lipoprotein-Cholesterol (LDL-C) at Week 12-53.8 ± 16.7
SecondaryMean Percent Change From Baseline of Total-Cholesterol (TC) at Week 12
Time frame:
Baseline and week 12
Reported as:
Mean · Percent Change
Mean Percent Change From Baseline of Total-Cholesterol (TC) at Week 12
Percent ChangeEzetimibe/Simvastatin 10/20 mg
Mean Percent Change From Baseline of Total-Cholesterol (TC) at Week 12-39.5 ± 12.2
SecondaryMean Percent Change From Baseline of High Density Lipoprotein-C (HDL-C) at Week 12
Time frame:
Baseline and week 12
Reported as:
Mean · Percent Change
Mean Percent Change From Baseline of High Density Lipoprotein-C (HDL-C) at Week 12
Percent ChangeEzetimibe/Simvastatin 10/20 mg
Mean Percent Change From Baseline of High Density Lipoprotein-C (HDL-C) at Week 129.4 ± 20.5
SecondaryMean Percent Change of Triglycerides From Baseline at Week 12
Time frame:
Baseline and week 12
Reported as:
Median · Percent Change
Mean Percent Change of Triglycerides From Baseline at Week 12
Percent ChangeEzetimibe/Simvastatin 10/20 mg
Mean Percent Change of Triglycerides From Baseline at Week 12-24.7 (-42.9 to -3.6)
Other pre-specifiedMean Change From Baseline of Low Density Lipoprotein-Cholesterol (LDL-C) at Week 12
Time frame:
Baseline and week 12
Reported as:
Mean · mg/dL
Mean Change From Baseline of Low Density Lipoprotein-Cholesterol (LDL-C) at Week 12
mg/dLEzetimibe/Simvastatin 10/20 mg
Mean Change From Baseline of Low Density Lipoprotein-Cholesterol (LDL-C) at Week 12-85.6 ± 31.7

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ezetimibe/Simvastatin 10/20 mg—1/173 (0.6%)34/173 (19.7%)
Most frequent serious events
Most frequent serious events
EventEzetimibe/Simvastatin 10/20 mg
Peptic UlcerGastrointestinal disorders1/173
Most frequent other events
Most frequent other events
EventEzetimibe/Simvastatin 10/20 mg
MyalgiaMusculoskeletal and connective tissue disorders7/173
Upper Respiratory InfectionInfections and infestations7/173
Increased Creatine Phosphokinase (CPK)Investigations6/173
DizzinessNervous system disorders5/173
Increased Serum Glutamic Pyruvic Transaminase (SGPT)Investigations5/173
FatigueGeneral disorders3/173
FlatulenceGastrointestinal disorders2/173
DiarrheaGastrointestinal disorders2/173

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ezetimibe/Simvastatin 10/20 mg
Mean57.9 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)Ezetimibe/Simvastatin 10/20 mg
Female100
Male73
Body Mass Index
Body Mass Index(kg/m2)Ezetimibe/Simvastatin 10/20 mg
Mean25.5 ± 3.4
Baseline value of Low Density Lipoprotein-C
Baseline value of Low Density Lipoprotein-C(mg/dL)Ezetimibe/Simvastatin 10/20 mg
Mean156.8 ± 30.8
Baseline value of Total Cholesterol
Baseline value of Total Cholesterol(mg/dL)Ezetimibe/Simvastatin 10/20 mg
Mean243.7 ± 43.9
Baseline value of High Density Lipoprotein-C
Baseline value of High Density Lipoprotein-C(mg/dL)Ezetimibe/Simvastatin 10/20 mg
Mean47.1 ± 11.4
Baseline value of Triglycerides
Baseline value of Triglycerides(mg/dL)Ezetimibe/Simvastatin 10/20 mg
Median145 (89 to 206)
Sitting Diastolic Blood Pressure
Sitting Diastolic Blood Pressure(mm Hg)Ezetimibe/Simvastatin 10/20 mg
Mean78.5 ± 10.2

1 further baseline measures are reported on the registry.

08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Huang JC, Lee TY, Liou MJ, Lin CM, Pei D, Chen ZC, Liu RT, Kwok CF. Begin with the real-world patients of non-goal-achieved hypercholesterolemia in taiwan through the ezetimibe/simvastatin tablet - The BRAVO Study. Curr Med Res Opin. 2011 Aug;27(8):1645-51. doi: 10.1185/03007995.2011.594425. Epub 2011 Jun 23. PubMed 21699369 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2007 to primary completion in Jul 2009, 23 months.

Results were first posted in Aug 2010, 1 year 1 month after primary completion.

Of 40 phase 4 interventional studies under Hypercholesterolemia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 23 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2008
First posted
Apr 8, 2008
StartActual
Aug 1, 2007
Primary completionActual
Jul 1, 2009
CompletionActual
Jul 1, 2009
Results first posted
Aug 26, 2010
Last update
May 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00654628
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Apr 8, 2008
Start date
Aug 1, 2007
Primary completion
Jul 1, 2009
Completion
Jul 1, 2009
Results posted
Aug 26, 2010
Last update
May 22, 2024

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ezetimibe · Simvastatin

Start the discussion